AI & Machine Learning Startups
Next-generation AI platforms for drug discovery
EvolutionaryScale
ESM-3 protein language model. Meta AI spinout. Programmable biology platform. $142M Series A.
Phenomic AI
AI drug discovery using cell morphology. Deep learning on cellular images. Montreal-based.
Arctoris
Ulysses platform for automated drug discovery. Cloud lab for AI-driven research. Oxford spinout.
Organ-on-Chip Innovators
Early-stage companies pushing MPS technology forward
Javelin Biotech
Multiplexed organ-chip systems. MIT spinout. Single-cell resolution analytics for drug screening.
Bi/ond
Dynamic organ-on-chip with real-time sensing. Eindhoven University of Technology spinout.
Aracari Biosciences
VascuLab platform for vascularized tissue models. Perfusable microvessels for drug delivery studies.
Quris AI
Patient-on-chip + AI integration. Predictive toxicology combining biology with machine learning.
Bioprinting & Tissue Engineering
Next-generation fabrication technologies
Readily3D
Tomographic volumetric bioprinting. EPFL spinout. Sub-second printing of complex structures.
Volumetric Inc
Rapid light-based bioprinting for vascularized tissues. Rice University and UT spinout.
Inventia Life Science
RASTRUM bioprinting platform for 3D cell culture. Australian innovation for drug discovery.
Organoid & iPSC Innovators
Emerging leaders in 3D tissue and stem cell technologies
System1 Biosciences
Vascularized brain organoids. UCSF spinout. Precision psychiatry and CNS disease modeling.
Newcells Biotech
iPSC-derived kidney and retinal models. Newcastle University spinout with NHS partnerships.
Accellta
iPSC suspension culture technology. Large-scale pluripotent stem cell production for industry.
Key Trends to Watch
Startups combining wet lab with AI are attracting highest valuations. Closed-loop discovery systems.
FDA Modernization Act 2.0 enabling faster adoption. First ISTAND qualifications achieved.
Solving the vascularization problem is key to scale. Multiple approaches emerging.
Big pharma actively seeking startup partnerships. Validation deals accelerating growth.
Explore More
Analyze the investment landscape in human simulation technologies